Literature DB >> 24352002

Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases.

Kosuke Tanaka1, Chikashi Terao1, Koichiro Ohmura2, Meiko Takahashi1, Ran Nakashima2, Yoshitaka Imura2, Hajime Yoshifuji2, Naoichiro Yukawa2, Takashi Usui2, Takao Fujii2, Tsuneyo Mimori2, Fumihiko Matsuda1.   

Abstract

Although the association between CYP3A5 polymorphism and blood concentration of tacrolimus (TAC) in patients with solid organ transplantation was established, whether the association is also true in patients with connective tissue disease (CTD) who usually receive small amount of TAC is uncertain. Here, we performed a quantitative linear regression analysis to address the association between CYP3A5 and blood TAC concentration in patients with CTD. A total of 72 patients with CTD were recruited in the current study and genotyped for rs776746 in CYP3A5, which showed strong association with TAC concentration in patients with solid organ transplantation. The blood trough concentration of TAC after taking 3 mg per day was retrospectively obtained for each patient. As a result, allele A of rs776746 showed a significant association with a decreasing blood concentration of TAC (P=0.0038). Those who are carrying at least one copy of the A allele displayed decreased mean concentration of TAC by 31.0% compared with subjects with GG genotype. Rs776746 is associated with concentrations of TAC in patients with CTD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352002     DOI: 10.1038/jhg.2013.129

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  20 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods.

Authors:  D A Bloch; B A Michel; G G Hunder; D J McShane; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; J F Fries; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

3.  Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis.

Authors:  Satoshi Takahashi; Keiju Hiromura; Noriyuki Sakurai; Takayuki Matsumoto; Hidekazu Ikeuchi; Akito Maeshima; Yoriaki Kaneko; Takashi Kuroiwa; Yoshihisa Nojima
Journal:  Mod Rheumatol       Date:  2010-12-29       Impact factor: 3.023

4.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

7.  Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.

Authors:  X-J Shi; F Geng; Z Jiao; X-Y Cui; X-Y Qiu; M-K Zhong
Journal:  J Clin Pharm Ther       Date:  2010-10-05       Impact factor: 2.512

8.  Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus.

Authors:  Ramin Vafadari; Rachida Bouamar; Dennis A Hesselink; Rens Kraaijeveld; Ron H N van Schaik; Willem Weimar; Carla C Baan; Teun van Gelder
Journal:  Ther Drug Monit       Date:  2013-08       Impact factor: 3.681

9.  Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Authors:  Norihiko Tsuchiya; Shigeru Satoh; Hitoshi Tada; Zhenhua Li; Chikara Ohyama; Kazunari Sato; Toshio Suzuki; Tomonori Habuchi; Tetsuro Kato
Journal:  Transplantation       Date:  2004-10-27       Impact factor: 4.939

Review 10.  Tacrolimus: a further update of its use in the management of organ transplantation.

Authors:  Lesley J Scott; Kate McKeage; Susan J Keam; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.